Acadia Pharmaceuticals(ACAD)

SAN DIEGO, CAPharmaceutical1 H-1B visas (FY2023)

Focus: Acadia is a San Diego-based public pharmaceutical company specializing in small-molecule neurology therapeutics, with a market presence anchored by its peak-stage blockbuster NUPLAZID. The company generated $726M in FY2025 revenue while maintaining 48% R&D intensity.

Neurology

Profile data last refreshed 58m ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Acadia Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Acadia Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$726M

Key Products

NUPLAZID

Parkinson's Disease Psychosis

$596M Part D

Peak10.8yr

Flagship asset generating 97% of revenue with patent protection through 2037; serotonin 5-HT2A inverse agonist addressing unmet need in PDP.

Help build intelligence for Acadia Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Leading position in Parkinson's disease psychosis with NUPLAZID generating $596M in Part D spending and peak-stage revenue trajectory
Balanced pipeline with Phase 3 programs in high-value indications (Lewy Body Dementia, Rett Syndrome, Prader-Willi) providing 12+ year patent runway
Strong R&D investment at 48% of revenue signals commitment to innovation beyond the flagship asset

Watch Out For

Extreme revenue concentration (97% from single product) creates significant business vulnerability and restructuring risk post-NUPLAZID LOE in 2037-2038
Negative net income in FY2024 (-$216M) and FY2025 (-$61M) despite growing revenue indicates operational profitability challenges and limited cash runway ($189M) relative to R&D burn

Generated by Claude from Acadia Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

DAYBUE

Rett Syndrome

$19M Part D

Peak16.7yr

Recently approved with DAYBUE STIX extended-release formulation launching; rare disease orphan indication with long LOE (2043) and limited competition.

Pipeline & Clinical Trials

Support program

Knee Arthropathy

N/A

Clinical Trials (1)

NCT06575621Knee-hip Surgery Wait-list Support Program

N/A

Virtual reality guided motor rehabilitation

Stroke Acute

N/A

Clinical Trials (1)

NCT06864741Virtual Reality Rehabilitation for Stroke Patients in the Hospital and at Home.

N/A

Observation of minor phenomena

Parkinson Disease

N/A

Clinical Trials (1)

NCT05240339Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)

N/A

Real-world non-interventional

Parkinson Disease Psychosis

N/A

Real-world, non-interventional

Parkinson Disease Psychosis

N/A

Clinical Trials (1)

NCT03152292The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

N/A

ACP-044

Osteoarthritis Pain

Phase 2

Clinical Trials (2)

NCT04855240Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy

Phase 2

NCT05008835Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee

ACP-103

Hallucinations

Phase 2

Clinical Trials (5)

NCT00477672A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Phase 3

NCT00550238A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

ACP-103

Schizophrenia

Phase 2

Clinical Trials (1)

NCT00361166Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

Phase 2

ACP-104

Schizophrenia

Phase 2

Clinical Trials (2)

NCT00490516ACP-104 in Acutely Psychotic Subjects With Schizophrenia

Phase 2

NCT00628420Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics

Phase 1

ACP-211

Major Depressive Disorder (MDD)

Phase 2

Clinical Trials (1)

NCT07284667ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Phase 2

trofinetide

Rett Syndrome

Phase 3

Clinical Trials (4)

NCT04181723Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

Phase 3

NCT04279314Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

Phase 3

carbetocin

Hyperphagia in Prader-Willi Syndrome

Phase 3

Clinical Trials (2)

NCT06173531Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Phase 3

NCT06420297OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

ACP-204

Lewy Body Dementia Psychosis

Phase 3

Clinical Trials (4)

NCT07095465Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

Phase 3

NCT06194799ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Phase 3

pimavanserin

Parkinson's Disease Psychosis

Phase 4

Clinical Trials (5)

NCT04809116Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept

Phase 4

NCT05357612Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

probiotics

Attention Deficit Hyperactivity Disorder

Phase 4

Clinical Trials (1)

NCT02035878Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression

Phase 2

L. helveticus R0052 and B. longum R0175

Attention Deficit Hyperactivity Disorder

Phase 4

Clinical Trials (1)

NCT02545634Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children

Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 6 approved products, 54 clinical trials

Top TAs: Neurology, Rare Diseases

H-1B (2023): 1 approval

SEC Filings: 2 available

Portfolio Health

Launch1 (17%)

Peak3 (50%)

Post-LOE2 (33%)

6 total products

Therapeutic Area Focus

Neurology

4 marketed34 pipeline

Rare Diseases

2 marketed4 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$726M40%

R&D Spend

$352M(48%)3%

Net Income

-$61M

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

NCT00658567A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Phase 3

NCT04776746Open-Label Extension Study of Trofinetide for Rett Syndrome

Phase 3

NCT06159673ACP-204 in Adults With Alzheimer's Disease Psychosis

Phase 2/3

NCT04292223Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Phase 4

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Acadia Pharmaceuticals(ACAD)

About Acadia Pharmaceuticals

Why Work Here

Key Products

Watch Out For

Products & Portfolio (2)

Key Products by Revenue

Other Products (1)

Pipeline & Clinical Trials

Open Jobs (0)

Financials (FY2025)

Visa Sponsorship